David S. Shames

1100 Long Dong Avenue
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer.

Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer.

Journal: Journal for immunotherapy of cancer

Published: July 01, 2026

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.

Journal: Nature communications

Published: June 24, 2025

Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials.

Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 30, 2025

Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel.

Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel.

Journal: Journal for immunotherapy of cancer

Published: April 08, 2025

Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents.

Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents.

Journal: JTO clinical and research reports

Published: January 22, 2025

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: August 30, 2024

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Journal: Nature

Published: August 20, 2024

NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.

NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.

Journal: The Journal of clinical investigation

Published: August 01, 2024

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.

DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer.

Journal: Molecular cancer

Published: July 29, 2024

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Journal: Nature

Published: May 30, 2024

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.

Journal: Nature communications

Published: May 23, 2024

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Journal: Nature

Published: March 14, 2024

Showing 1-12 of 77

Last Updated: 09/26/2026